Related Experiment Video
Updated: Jun 24, 2026
Retroviral Transduction of T-cell Receptors in Mouse T-cells
Published on: October 22, 2010
Preclinical development of T cell receptor gene therapy
Gavin M Bendle1, John B A G Haanen, Ton N M Schumacher
1Division of Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. g.bendle@nki.nl
Abstract:
The adoptive transfer of TCR gene-modified T cells has been developed with the aim to induce immune reactivity toward defined tumor-associated antigens to which the endogenous T cell repertoire is non-responsive. Here we discuss in which areas preclinical studies in mouse models can or cannot be expected to be of value to guide clinical trial design, and how the available data from preclinical studies should influence forthcoming clinical trials.
Insights
Preclinical studies using T-cell receptor (TCR) gene-modified T cells can guide clinical trials by identifying effective strategies for targeting tumor antigens. However, their predictive value varies, requiring careful interpretation to optimize patient treatment.
Area of Science:
- Immunotherapy
- Oncology
- T-cell engineering
Background:
- Adoptive T-cell transfer utilizes T-cell receptor (TCR) gene-modified T cells to target tumor antigens.
- This approach aims to overcome the limitations of the endogenous T-cell repertoire in responding to specific tumor-associated antigens.
- Current strategies focus on enhancing anti-tumor immune responses through engineered T cells.
Purpose of the Study:
- To evaluate the utility of preclinical mouse models in guiding the design of clinical trials for TCR gene-modified T-cell therapies.
- To determine the limitations and strengths of preclinical data in predicting clinical outcomes.
- To provide recommendations on how preclinical findings should inform the development of future clinical trials.
Main Methods:
- Review and analysis of existing preclinical studies in mouse models involving TCR gene-modified T cells.
- Comparison of data from preclinical studies with available clinical trial data.
- Identification of discrepancies and consistencies between preclinical predictions and clinical observations.
Main Results:
- Preclinical models show promise in predicting efficacy for certain tumor-associated antigens but have limitations.
- The predictive value of mouse models is dependent on the specific antigen and tumor context.
- Variability in T-cell persistence, trafficking, and tumor microenvironment interactions in preclinical models impacts translatability.
Conclusions:
- Preclinical studies are valuable for initial strategy development but require cautious interpretation for clinical trial design.
- Further refinement of preclinical models is needed to better mimic the human immune system and tumor microenvironment.
- Clinical trial design should incorporate adaptive strategies informed by both preclinical data and early clinical findings.
